<DOC>
	<DOCNO>NCT00693433</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together dexamethasone treat patient recurrent refractory multiple myeloma . Temsirolimus may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving temsirolimus together dexamethasone may kill cancer cell .</brief_summary>
	<brief_title>Temsirolimus Dexamethasone Treating Patients With Recurrent Refractory Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess toxicity safety temsirolimus combination dexamethasone patient recurrent refractory multiple myeloma . II . To assess dose temsirolimus capable inhibit mammalian target rapamycin ( mTOR ) myeloma tumor cell . SECONDARY OBJECTIVES : I . To assess efficacy temsirolimus combination dexamethasone patient . II . To correlate efficacy regimen molecular characteristic individual tumor clone . OUTLINE : This multicenter , dose-escalation study temsirolimus . Patients receive temsirolimus intravenously ( IV ) 30 minute weekly day 1 , 8 , 15 , 22 oral dexamethasone day 1 , 2 , 8 , 9 , 15 , 16 , 22 , 23 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo bone marrow aspiration blood sample collection periodically correlative study . Correlative study include analysis p70S6 kinase activity peripheral blood mononuclear cell multiple myeloma cell ; analysis degree AKT phosphorylation degree PTEN expression multiple myeloma cell immunohistochemistry ; Ras mutational analysis ; Myc 5'UTR mutational analysis . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Pathologically confirm multiple myeloma Measurable level M protein serum and/or urine Recurrent refractory disease Progressive disease treatment ≥ 2 separate chemotherapeutic regimen At least 1 regimen must include highdose dexamethasone ( 40 mg day 14 , 912 , 1720 ) mediumdose dexamethasone ( 40 mg day 1 , 8 , 15 , 22 ) 28day course ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy ≥ 8 week Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm ^3 Total bilirubin &lt; 2 mg/dL AST ALT &lt; 3 time upper limit normal Creatinine &lt; 2 mg/dL Fasting cholesterol &lt; 350 mg/dL Fasting triglycerides &lt; 400 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biological composition temsirolimus dexamethasone No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Poorly control hypertension Diabetes mellitus Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement See Disease Characteristics At least 4 week since prior cytotoxic therapy More 4 week since prior chemotherapy recover No concurrent anticonvulsive antiarrhythmic medication No concurrent enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inhibitor inducer ( e.g. , rifampin Hypericum perforatum [ St. John wort ] ) No concurrent prophylactic hematopoietic colonystimulating factor No concurrent investigational therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>